MLSS · Milestone Scientific Inc.
The AI's read
Milestone reported Q2 revenue up 22% to $2.8 million, led by CompuFlo's medical segment growing 231% year-over-year. Management also announced a Red One distribution agreement and a third-party study showing a 91% reduction in complications. The stock barely moved, up 0.15%, and RSI sits at 51.62, so the market has not priced this surge in medical revenue aggressively. Management reaffirmed full-year 2026 guidance but flagged a Q3 sequential revenue dip from one-off international orders and seasonality. We lean bullish: Medicare reimbursement tailwinds, rapid medical adoption, new distribution reach, and clinical validation create clear upside potential. This is a microcap with execution and seasonality risk, so size positions accordingly and expect volatility.